A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium

Completed

• Conditions: Psoriasis
• Interventions: Drug: Apremilast

• Registration Number: NCT03097003
• Lead Sponsor: Amgen

Brief Summary

OTELO is a national (Belgium), multicentre, prospective, non-interventional, post-marketing study. The study will include a representative sample of approximately 250 patients with moderate-to-severe plaque psoriasis for whom the treating dermatologist has decided to begin apremilast treatment in accordance with the local label and reimbursement criteria. Patients may be enrolled into the study up to 4 weeks after commencing the study treatment.

As this study is non-interventional, drug dosing and treatment duration will be at the sole discretion of the treating dermatologist, in accordance with the local label and daily clinical practice.

Detailed Description

Patient care will follow routine clinical practice, involving regular follow-up visits, without any mandatory visit. In daily practice, patients are usually seen by their treating dermatologists every 3 months. In this study, patients will be followed-up for a least 6 months and at most 18 months after apremilast treatment initiation. Patient data will be collected until 31st December 2018. Assuming a recruitment phase of 18-month duration starting as of December 2016, individual patient follow-up times will range from 6 to 18 months, depending on the inclusion date. During the first months of the study, the recruitment rate has been slower than expected. Therefore, it has been decided in October 2017 to increase the period of recruitment to 18 months in order to have enough evaluable patients to keep the accuracy required for the statistical analysis.

During the study, it is expected to collect data at inclusion and at 6 months after apremilast initiation in all patients. As per NIHDI recommendations, patients should consult their treating dermatologists 6 months after apremilast initiation in order to evaluate treatment response and decide on treatment continuation for an additional period of 12 months. For patients recruited early in the study, data will be collected during the next follow-up visits up to 18 months after apremilast initiation. Only data pertaining to visits occurring at 9 (± 1), 12 (± 1), 15 (±1), and 18 (± 1) months after treatment initiation will be collected. If a study visit occurs approximately 3 (± 1) months after treatment initiation, the data will also be recorded.

All clinical data collected during this non-interventional study will be routinely documented in the patient's medical records, which are the main source of information. The study data will be collecting via an eCRF. Data from source documents including PRO-questionnaires will be entered in the eCRF by the investigator or other authorised appropriately designed and trained study site personnel. Data entered into the eCRF will be reviewed for consistency by the Data Manager using both automated logical checks (issuing in automatic queries generated by the system) and manual review (issuing in manual checks set by the Data Manager or the Monitor into the eCRF). All data collected within the eCRF will be approved and electronically signed and dated by the Investigator or designee. At the conclusion of the study, before the final statistical analysis, the eCRF and other study data will be locked to further additions or corrections.

During the study, the Clinical Research Associate (CRA) will contact each study site on a regular basis in order to check the progress and conduct of the study. If issues regarding study conduct arise, additional on-site visits may be performed. In particular, a quality analysis will also be performed and based on data quality, it will be decided whether on-site monitoring is necessary, for which site and on which percentage of patients. During monitoring visits, eCRFs, patient's source documents, and all other study documentation will be reviewed by the CRA. Accuracy will be checked by performing source data verification that is a direct comparison of the entries made onto the eCRF against the appropriate source documentation.

Adverse events AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. The detailed methodology of the statistical analyses will be documented in a statistical analysis plan (SAP). The SAP will be written by the Clinical Research Organisation (CRO) in charge of the study and will be validated by sponsor prior to performing the analysis and obligatory before the database lock. A scientific committee has been selected for this study. This committee will provide advice on the SAP.

Study Timeline

• Study First Submitted: 2017-03-24
• Study First Submitted QC: 2017-03-24
• Study First Posted: 2017-03-31
• Study Start: 2017-04-06
• Primary Completion: 2018-12-20
• Study Completion: 2018-12-20
• Status Verified: 2020-04
• Last Update Submitted: 2020-04-24
• Last Update Posted: 2020-04-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 124

Inclusion Criteria

• Patients who meet ALL the following criteria can be enrolled:

• Male or female aged at least 18 years.
• With a diagnosis of moderate-to-severe chronic plaque psoriasis. As per Belgian National Institute for Health and Disability Insurance (NIHDI), moderate-to-severe plaque psoriasis in adult patients is defined by a Body Surface Area (BSA) > 10% or aPsoriasis Area and Severity Index (PASI) > 10.
• For whom the treating dermatologist has made the decision to commence apremilast treatment in accordance with the local label and reimbursement criteria
• Able to follow the instructions of the study.
• Having signed an Informed Consent Form (ICF)

Exclusion Criteria

Patients who meet AT LEAST one of the following exclusion criteria will be excluded:

• Patients who have received apremilast > 4 weeks prior to the enrolment visit.
• Women who are pregnant, breastfeeding or planning on becoming pregnant.
• Non-menopausal women who are not using an adequate contraception method.
• Patients with hypersensitivity to apremilast or to one of its excipients.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Use of Apremilast in patient with plaque psoriasis	Apremilast	Psoriasis patients treated with Otezla® (Apremilast) in Belgium

Primary Outcome Measures

Name	Time	Method
Proportion of patients with Patient Benefit Index for skin diseases (standard version) (PBI-S) ≥ 1 at 6 months after apremilast initiation.	Up to 6 Months	The PBI-S questionnaire for skin diseases is a validated instrument to assess treatment needs and benefits in patients with skin diseases. It comprises 23 items on patient-relevant therapy needs and benefits.

Secondary Outcome Measures

Name	Time	Method
Characteristics of the patients treated with apremilast	Baseline	The patients treated with Apremilast will be described according to the following characteristics: demographics (age, gender, weight, height, and ethnicity), professional status, lifestyle habits, medical history (including psoriasis treatment history), and comorbidities
Change from baseline in the DLQI score after apremilast initiation	up to 18 months	DLQI is 10-item validated questionnaire used in a wide range of dermatological conditions and across a wide range of disease severity as a quality of life instrument. It covers a variety of health dimensions, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Each item is graded on a Likert scale of 0-3, which gives an overall score ranging from 0 to 30 where lower scores mean better quality of life.
Change from baseline in the disease activity scores in terms of PASI	up to 18 months	PASI is common clinical tool used to measure the severity and extent of psoriasis. PASI score is a composite score grading the severity of psoriasis in four body regions according to erythema, scaling, and thickness, and the total area of skin affected. The final composite score ranges from 0 to 72, with a higher score indicating a greater severity of psoriasis. PASI 50 and PASI 75 responses were defined as \>=50% and \>= 75% improvement in overall PASI score when compared to baseline
PBI-S outcome score after apremilast initiation	up to 18 months	The PBI-S questionnaire for skin diseases is a validated instrument to assess treatment needs and benefits in patients with skin diseases. It comprises 23 items on patient-relevant therapy needs and benefits.
Change from baseline in the PtGA after apremilast initiation	up to 18 months	PtGA is defined as single-item 5-point categorised scale reflecting the patient's overall impression of psoriasis severity. This scale ranges from 0 (clear/no psoriasis) to 4 (severe psoriasis)
Change from baseline in the disease activity scores in terms of Body Surface Area (BSA)	up to 18 months	BSA is measurement of the body area involved in relation to the whole body surface.
Proportion of patients with PBI-S = 4 at 6 months after apremilast initiation	Up to 6 Months	The PBI-S questionnaire for skin diseases is a validated instrument to assess treatment needs and benefits in patients with skin diseases. It comprises 23 items on patient-relevant therapy needs and benefits.
Change from baseline in the psoriasis symptomatology	up to 18 months	Psoriasis symptomatology - pruritus, scalp psoriasis, nail psoriasis, skin discomfort/pain, joint pain, fatigue, overall wellbeing. Each symptom will be graded using a 7-grade discrete rating scale
Rate of discontinuation of apremilast treatment within 6 months after initiation	Up to 6 months	Descriptive statistics will be provided for the rate and reasons for discontinuation of treatment within 6 months. This analysis will be performed on safety population and restricted to patients who stop the treatment before the time point to analyse or for which the follow-up is at least so long as the time point to analyse.
Proportion of patients having clear/no psoriasis based on Patient Global Assessment (PtGA) at 6 months after apremilast initiation	up to 6 months	PtGA is defined as single-item 5-point categorised scale reflecting the patient's overall impression of psoriasis severity. This scale ranges from 0 (clear/no psoriasis) to 4 (severe psoriasis)
Proportion of patients with Dermatology Life Quality Index (DLQI) ≤ 5 at 6 months after apremilast initiation.	Up to 6 Months	DLQI is 10-item validated questionnaire used in a wide range of dermatological conditions and across a wide range of disease severity as a quality of life instrument. It covers a variety of health dimensions, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Each item is graded on a Likert scale of 0-3, which gives an overall score ranging from 0 to 30 where lower scores mean better quality of life.
Change from baseline in the patient-reported treatment satisfaction (TSQM-9)	up to 18 months	TSQM-9 is 9-item validated self-administered questionnaire used to evaluate the patient's overall satisfaction with study treatment. The TSQM-9 consists of 8 items that make up 3 specific scales (effectiveness, side effects, convenience) and one global satisfaction scale. Scale scores are transformed into scores from 0 to 100 with higher scores representing higher satisfaction in that domain.
Mean duration of apremilast treatment in biologic-naïve patients and in patients having received a previous biological treatment	Up to 18 Months	Time to the stop of the treatment by Apremilast will be calculated as the time interval from the date of apremilast initiation to the date of the apremilast stop
Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 50 or PASI 75 at 6 months after apremilast initiation	Up to 6 Months	PASI is common clinical tool used to measure the severity and extent of psoriasis. PASI score is a composite score grading the severity of psoriasis in four body regions according to erythema, scaling, and thickness, and the total area of skin affected. The final composite score ranges from 0 to 72, with a higher score indicating a greater severity of psoriasis. PASI 50 and PASI 75 responses were defined as \>=50% and \>= 75% improvement in overall PASI score when compared to baseline
Adverse Events (AEs)	Up to 18 months	Number of participants with adverse event

Trial Locations

Locations (22)

Ste Elisabeth - Namur; 🇧🇪 Namur, Belgium

CH Bois Abbaye-Hesbaye; 🇧🇪 Seraing, Belgium

Private Practice Lede; 🇧🇪 Lede, Belgium

CHU Sart-Tilman; 🇧🇪 Liège, Belgium

AZ Sint Jan; 🇧🇪 Brugge, Belgium

Clin Univ de Bxl Hôpital Erasme; 🇧🇪 Brussels, Belgium

UZ Brussel; 🇧🇪 Brussels, Belgium

Cliniques Universitaires St-Luc; 🇧🇪 Brussels, Belgium

Private Practice Genk; 🇧🇪 Genk, Belgium

AZ Sint Lucas; 🇧🇪 Gent, Belgium

Clinique André Renard d'Herstal; 🇧🇪 Herstal, Belgium

UZ Leuven Sint Rafael; 🇧🇪 Leuven, Belgium

CHU UCL Mont-Godinne; 🇧🇪 Godinne, Belgium

UZ Antwerpen; 🇧🇪 Edegem, Belgium

Private Practice Geel; 🇧🇪 Geel, Belgium

Private Practice Mons; 🇧🇪 Mons, Belgium

CHU St Pierre; 🇧🇪 Brussels, Belgium

CHU Brugmann (Victor Horta); 🇧🇪 Brussels, Belgium

Private Practice Namur; 🇧🇪 Namur, Belgium

UZ Gent; 🇧🇪 Gent, Belgium

GHdC - site IMTR; 🇧🇪 Loverval, Belgium

Dermatologie Maldegem; 🇧🇪 Malgegem, Belgium